Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Stock Has Average Price Target of $100.57 According to Brokerages

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) has been assigned a consensus rating of “Moderate Buy” from the nine ratings firms that are covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $100.57.

KNSA has been the topic of several research analyst reports. Weiss Ratings cut Kiniksa Pharmaceuticals International from a “buy (b-)” rating to a “hold (c-)” rating in a research note on Wednesday, October 28th. JPMorgan Chase & Co. upped their target price on Kiniksa Pharmaceuticals International from $107.00 to $122.00 and gave the company an “overweight” rating in a report on Friday, October 30th. Canaccord Genuity Group raised their price target on Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the stock a “buy” rating in a research note on Wednesday, July 29th. The Goldman Sachs Group lifted their price target on shares of Kiniksa Pharmaceuticals International from $90.00 to $101.00 and gave the company a “buy” rating in a report on Wednesday, October 28th. Finally, Zacks Research cut shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 30th.

Kiniksa Pharmaceuticals International Trading Up 0.1%

KNSA stock opened at $96.33 on Friday. The firm’s 50-day moving average price is $82.18 and its two-hundred day moving average price is $62.70. Kiniksa Pharmaceuticals International has a 12-month low of $37.02 and a 12-month high of $99.31. The stock has a market capitalization of $7.57 billion, a price-to-earnings ratio of 74.10 and a beta of 0.07.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last released its quarterly earnings results on Tuesday, October 27th. The company reported $0.56 EPS for the quarter, beating analysts’ consensus estimates of $0.37 by $0.19. Kiniksa Pharmaceuticals International had a return on equity of 17.27% and a net margin of 11.58%. The business had revenue of $285.97 million during the quarter, compared to analyst estimates of $260.66 million. Equities analysts predict that Kiniksa Pharmaceuticals International will post 1.30 EPS for the current year.

Insider Transactions at Kiniksa Pharmaceuticals International

In related news, CFO Mark Ragosa sold 36,783 shares of the business’s stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $92.16, for a total transaction of $3,389,921.28. Following the transaction, the chief financial officer owned 20,854 shares in the company, valued at $1,921,904.64. The trade was a 63.82% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider John F. Paolini sold 18,413 shares of the stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $93.39, for a total transaction of $1,719,590.07. Following the completion of the transaction, the insider directly owned 69,922 shares of the company’s stock, valued at approximately $6,530,015.58. The trade was a 20.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 842,302 shares of company stock worth $78,587,130. 51.98% of the stock is owned by corporate insiders.

Institutional Trading of Kiniksa Pharmaceuticals International

Large investors have recently bought and sold shares of the company. Allworth Financial LP raised its holdings in Kiniksa Pharmaceuticals International by 42.0% in the 2nd quarter. Allworth Financial LP now owns 453 shares of the company’s stock worth $29,000 after acquiring an additional 134 shares during the last quarter. Arizona State Retirement System boosted its stake in Kiniksa Pharmaceuticals International by 2.1% during the 2nd quarter. Arizona State Retirement System now owns 10,132 shares of the company’s stock valued at $648,000 after purchasing an additional 209 shares during the last quarter. GAMMA Investing LLC boosted its stake in Kiniksa Pharmaceuticals International by 21.1% during the 3rd quarter. GAMMA Investing LLC now owns 1,278 shares of the company’s stock valued at $95,000 after purchasing an additional 223 shares during the last quarter. Commonwealth Equity Services LLC boosted its stake in Kiniksa Pharmaceuticals International by 2.2% during the 3rd quarter. Commonwealth Equity Services LLC now owns 10,871 shares of the company’s stock valued at $811,000 after purchasing an additional 237 shares during the last quarter. Finally, First Trust Advisors LP increased its holdings in shares of Kiniksa Pharmaceuticals International by 3.1% in the 1st quarter. First Trust Advisors LP now owns 9,876 shares of the company’s stock worth $476,000 after purchasing an additional 293 shares in the last quarter. 53.95% of the stock is owned by institutional investors.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International plc is a biopharmaceutical company focused on developing and commercializing treatments for patients with autoimmune and inflammatory diseases. The company was established in 2015 and has operations in the United States and internationally. Kiniksa’s marketed medicine, Arcalyst (rilonacept), is approved in the United States to treat recurrent pericarditis and reduce the risk of recurrence in adults and certain pediatric patients. It is also approved for cryopyrin-associated periodic syndromes, a group of rare autoinflammatory conditions.